Home > Insider Trading > Filing (0001209191-23-032726)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
899460	Mannkind Corp	MNKD	Pharmaceutical Preparations (2834)	133607736

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1674282	Michael Castagna	1 Casper Street Danbury CT 06810	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $.01 Par Value	Acquisiton	2023-05-25	345,000	$0.00	2,676,735	No	4	A	Direct
Common Stock, $.01 Par Value	Disposition	2023-05-25	75,000	$4.59	2,601,735	No	4	S	Direct
Common Stock, $.01 Par Value	Disposition	2023-05-26	75,000	$4.50	2,526,735	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, $.01 Par Value	Performance Restricted Stock Unit	Acquisiton	2023-05-25	422,000	$0.00	422,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
422,000			No	4	A	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested.
Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022.
The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.